Glutathione Peptide Dosing Guide: Optimal Protocols

Overview

Glutathione is a research peptide discussed for its potential effects. This guide provides an educational overview of Glutathione dosing patterns based on published research and peptide community discussions, presented as a text-based dosage chart for discussion with a licensed healthcare provider. You can use our Glutathione dosage calculator → to plan protocol schedules and check reconstitution math — for educational purposes only.

What is Glutathione?

Glutathione is a peptide compound discussed in research contexts.

Key characteristics:

Mechanism:
Route: intravenous or intramuscular injection
Legal status: Not FDA-approved — research only
Half-life: minutes (IV)
Category:

To calculate your protocol dosing, see our Glutathione dosage calculator →

Glutathione dosage chart

There is no established FDA-approved dose for Glutathione. The chart below summarizes dosing patterns drawn from published research protocols and peptide community discussions. It is intended for educational reference only — not as a personal dosing plan or medical recommendation.

Protocol Phase	Dose Range	Route	Frequency	Duration	Use Case
Standard	600 mg	IV / IM injection	1-3x weekly	4-8 weeks	Antioxidant research protocol
Lower-dose exploratory	100-200 mg	IM injection	1-2x weekly	4 weeks	Conservative start
Higher-dose	1200 mg	IV injection	1-3x weekly	4-8 weeks	Upper discussed range
Cycle break	No dose	—	—	As advised	Recovery period

For dose calculations, reconstitution math, and syringe unit conversions, see our Glutathione dosage calculator →

How Glutathione works

Glutathione

Understanding the pharmacokinetic profile helps explain the dosing patterns. minutes (IV)

For quick dose calculations based on these protocols, use our Glutathione dosage calculator →

Administration routes

Glutathione is commonly discussed as administered via intravenous or intramuscular injection in research literature. The choice of route affects bioavailability, onset, and duration of effect.

For reconstitution math and syringe unit calculations, see our Glutathione dosage calculator →

Cycle structure and timing

Research protocols for Glutathione typically follow a cycle structure with distinct phases: loading, maintenance, and recovery. The specific duration of each phase depends on the research context and should be discussed with a qualified professional.

Safety considerations

Glutathione is not FDA-approved for human use. All dosing information in this guide is presented for educational and research purposes only. Consult a licensed healthcare provider before considering any peptide protocol.

Frequently asked questions

See the FAQ section below for common questions about Glutathione dosing, administration, and research status.

Related Peptides

Frequently Asked Questions

What is the typical dose of Glutathione?

Research protocols typically discuss the ranges shown in our Glutathione dosage chart (1-3x weekly (research), intravenous or intramuscular injection). These ranges are drawn from published research and community discussion, not FDA-approved clinical guidelines. No established therapeutic dose exists for Glutathione.

How is Glutathione administered?

Glutathione is typically discussed as administered via intravenous or intramuscular injection in research literature. The specific route depends on the research protocol and should be discussed with a qualified professional.

Is Glutathione FDA-approved?

No. Glutathione is not FDA-approved for any therapeutic use. Regulations vary by jurisdiction. All information presented here is for educational and research purposes only.

What is the half-life of Glutathione?

The half-life of Glutathione is approximately minutes (IV). This information is based on limited research data and should not be used for personal dosing decisions.

What are the side effects of Glutathione?

Side effects are compound-specific and not fully characterized in human studies. Potential effects include injection site reactions, mild headache, or transient changes in the target system. Discuss any reactions with a healthcare provider.